IDXG — Interpace Biosciences Income Statement
0.000.00%
Last trade - 00:00
- $6.35m
- $12.19m
- $40.21m
- 61
- 99
- 72
- 91
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K/A | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 24.2 | 32.4 | 33.1 | 31.8 | 40.2 |
Cost of Revenue | |||||
Gross Profit | 8.33 | 10.7 | 18.8 | 18.2 | 23.9 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 50.7 | 58.5 | 39.5 | 35.5 | 37.4 |
Operating Profit | -26.4 | -26.1 | -6.34 | -3.62 | 2.8 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -26.7 | -26.1 | -7.74 | -5.84 | 1.13 |
Provision for Income Taxes | |||||
Net Income After Taxes | -27.5 | -27.1 | -7.04 | -5.87 | 1.11 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -26.7 | -26.5 | -14.9 | -22 | 0.802 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -27.2 | -29.5 | -14.9 | -22 | 0.802 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -6.86 | -7.48 | -1.56 | -1.38 | 0.255 |